Post on 26-Jun-2020
II. YB-1 knockdown induces apoptosis or G0/G1 cell cyclearrest, cisplatin sensitisation and impedes the migrationof MPM cells.Transfection of YB-1 siRNA induced (A) apoptosis or (B) an increasein G0/G1 population in MPM cells. (C) Cells undergoing apoptosisafter YB-1 downregulation were sensitised to cisplatin, one of the mostcommonly prescribed drugs to patients suffering this disease, while aslight increase in resistance was seen in cells undergoing cell cyclearrest. (D) YB-1 silencing significantly inhibited MPM cell migration.
A
C
BackgroundMalignant pleural mesothelioma (MPM) is an aggressive asbestos-related malignancy with extremely poor prognosis, with a 5 year survival of approximately 5%. MPM remains difficult to treat - the current standard of chemotherapy care (a combination of cisplatin and pemetrexed) has been largely unchanged over the last decade and in most cases, is essentially palliative. Novel therapeutic targets are therefore urgently needed in this disease. Y-box binding protein-1 (YB-1) is a multifunctional oncoprotein associated with all of the hallmarks of cancer. Here, we evaluate YB-1 as a therapeutic target in this disease by investigating its role in driving malignant behaviour and chemoresistance of MPM cells.
AcknowledgementsThis work was supported by a scholarship from the Asbestos Diseases Foundation of Australia, a Top-Up Scholarship from Sydney Catalyst and a Cancer Institute of NSW grant.
Contact detailsThomas Johnson – e: tjoh9110@uni.sydney.edu.auKarin Schelch – e: karin.schelch@meduniwien.ac.at
Figure II: (A) Cells were transfected with 5 nM YB-1, RRM1 (+Co) or control (-Co) siRNA andincubated for 96 h. Live cells were then stained with Annexin V-488 conjugate and propidium iodideand a TALI-image based cytometer was used to measure apoptosis, or (B) fixed and stained withpropidium iodide and cell flow cytometry was conducted. (C) 2000 cells were transfected with 5 nMof YB-1 or control (Co) siRNA. The next day, cells were treated with cisplatin and a SYBR greenbased proliferation assay was employed after 96 h, normalising to the cisplatin negative cells ofeach different siRNA group. (D) Cells were transfected with 5 nM of YB-1 siRNA, 25,000 cells wereplated and videomicroscopy performed. Single cell migration was manually tracked via Image Jover 25 h (n=3). A students t-test was used to determine statistical significance (***p>0.001).
III. YB-1 is important in MPM tumour formation in vivo.MSTO cells stably expressing luciferase were transfected with 5 nM ofeither YB-1 or control (Co) siRNA and the next day intraperitoneally(IP) injected injection into SCID mice (n=5 per group). (A) Tumourgrowth was monitored in situ using the IVIS imaging system afterluciferin substrate injection. (B) Detection of bioluminescence wasalso used to visualise tumour nodules when harvested. (C) Totaltumour weight was significantly lower in mice injected with YB-1 vs CosiRNA transfected cells.
Co si-YB-1
4 weeks after injectionB
Co si-YB-1
3 weeks after injectionA
IV. YB-1 is overexpressed in MPM cells with acquiredchemoresistance, and these cells have heightenedmigratory capacity compared to their parental lines.MPM cells were grown in medium supplemented with IC50concentrations of either cisplatin, gemcitabine or vinorelbine – allcommonly prescribed drugs in the management of MPM – until theydisplayed >2 fold increase in IC50 to that drug. (A) YB-1 wasupregulated in cell lines with acquired drug resistance (drugR cells)compared to respective parental cells. (B) There was no significantdifference in growth rate, but (C) drug resistant cells displayedsignificantly increased migratory capacity compared to parental cells.
Figure IV: (A) Protein was harvested from untreated cells and Western Blot analysis of YB-1 wasconducted using β-actin as loading control. Densitometry analysis on Image J allowed aquantitative comparison between parental and drug resistant cell lines, after normalising to β-actin. (B) 2000 untreated cells per well were grown for 96 h and a SYBR green basedproliferation assay was conducted. (C) 25000 cells were plated and single cell migration wasmanually tracked via videomicroscopy on Image J over 25 h. A students t-test was used todetermine statistical significance (*** p>0.001)
ResultsI. YB-1 is overexpressed in MPM and silencing inhibits MPM,but not non-malignant mesothelial proliferation.(A) YB-1 protein was overexpressed in most MPM cell lines compared tothe immortalised mesothelial cell line MeT-5A. (B) YB-1 knockdown viasiRNA transfection did not affect MeT-5A proliferation, but did significantlyinhibit MPM cell growth (4/6 cell lines) and (C) colony formation.
Figure I: (A) Protein was harvested from untreated MPM or MeT-5A cells and Western Blot analysis ofYB-1 was conducted using β-actin as loading control. Overexpression compared to MeT-5A wasconfirmed in at least 2 repeats per cell line (representative blot shown here)
YB-1
b-actin
A
Figure I:(C) Cells were transfectedwith 5 nM of YB-1 or control(-Co) siRNA, seeded (2,000cells per well) and grownuntil colonies formed (n=2,representative photos shownhere). RRM1 siRNA wasused as positive control(+Co)
C
Figure I:(B) 2000 cells (triplicates) per96-well were transfected with5 nM of YB-1, or control (Co)siRNA and incubated for 96 h.Proliferation was determinedusing a SYBR green basedgrowth assay (n=3). A studentst-test was used to determinestatistical significance(**p>0.01, ***p>0.001).
B
B
Figure III: Mice were injected with MPM cells transfected with 5 nM YB-1 (si-YB-1) or control (Co)siRNA, monitored regularly and humanely euthanised 4 weeks after injection (A) Mice wereanesthetised via IP injection of 100 mg/kg ketamine and 10 mg/kg xylazine. 200 µL VivoGlo™luciferin was injected IP, with IVIS images being taken 10 minutes later. Representative photographswere taken at 3 weeks post injection. (B) Mice were anesthetised and humanely euthanised viacervical dislocation. Tumour tissue was visualised on a ChemiDoc™ Gel imaging system by pipettingVivoGlo™ luciferin into the peritoneal cavity and resected. (C) Total tumour weight was measured(n=5 mice per group). A students t-test was used to determine statistical significance (*p>0.05)
YB-1:animportantdriverofmesotheliomadrugresistanceandapotentialnoveltherapeutictarget
ThomasJohnson1,2,3,KarinSchelch4,KadirSarun1,MarissaWilliams1,2,YuenYeeCheng1,AnnetteLasham5,GlenReid21TheAsbestosDiseasesResearchInstitute,Sydney,Australia;2SchoolofMedicine,TheUniversityofSydney,Australia;3SydneyCatalystTranslationalCancerResearchCentre,Australia;4InstitueofCancerResearch,MedicalUniversityofVienna,Austria;
5DepartmentofMolecularMedicineandPathology,SchoolofMedicalSciences,UniversityofAuckland,Auckland,NewZealand
YB-1 siRNA transfection
MeT-5A H28 Ren
MSTOMMO5
SPC212
VMC230
20
40
60
80
100
** ** ******
Cel
l gro
wth
(% C
o)
C
MSTO par
MSTO cisR
MSTO gemR
MSTO vinR
MMO5 par
MMO5 gemR0
100
200
% of pa
rental
cell line
YB-1
b-actin
1.0 1.34 2.41 1.87 1.0 1.47
A
p a r
g emR
v inR
0
5 0
1 0 0
1 5 0
2 0 0
mig
rate
d d
ista
nce
(µ
m)
M S T O
* * * * * *
p a rc is
R
g emR
v inR
0
2 5
5 0
7 5
1 0 0
1 2 5
ce
ll g
row
th (
% p
are
nta
l)
M S T O
B C
1 10 1000
2 5
5 0
7 5
1 0 0
C is p la tin (µM )
cell
gro
wth
(% v
eh
icle
tre
ate
d)
1 10 1000
2 5
5 0
7 5
1 0 0
C is p la tin (µM )
% c
ell
gro
wth
(ve
hic
le t
rea
ted
)
-C o
1 n M5 n M
D
-Co
s i-YB -1
0
2 0
4 0
6 0
8 0
1 0 0
mig
rate
d d
ista
nce
(µ
m)
* * *
-Co
s i-YB -1
0
5 0
1 0 0
1 5 0
mig
rate
d d
ista
nce
(µ
m)
* * *
ConclusionsYB-1 is a potential novel therapeutic target in MPM. Itplays an important role in the growth and migration ofMPM cells, can sensitise cells to cisplatin in vitro andis important in the growth of tumours in vivo. Ourfindings also indicate that this protein is involved in theacquired chemoresistance of MPM. Taken together,our data make a strong case to further investigate thisoncogene’s potential as a therapeutic target in MPM.
Co siYB-1
Apoptotic DeadLate apoptotic Alive
MSTO
REN
CoYB1
0.0
0.2
0.4
0.6
Tota
l tum
our w
eigh
t (g)
*
MSTO REN
MSTO REN
MSTO REN
Sub G-1 G0/G1S G2/M
Co
si-YB1
0
50
100
% o
f pop
ulat
ion
Co
si-YB1
0
50
100
% o
f pop
ulat
ion